CHRONIC PLAQUE PSORIASIS

This study tested a drug called tildrakizumab in 99 adults with moderate to severe nail psoriasis, a condition causing nail damage and pain. Participants received either the drug or a placebo for 28 weeks. The goal was to see if the drug improves nail appearance and reduces pain.…

This study tested a drug called bimekizumab in 133 Chinese adults with moderate to severe plaque psoriasis. Participants received either the drug or a placebo for 16 weeks. The main goal was to see if bimekizumab could significantly clear skin compared to placebo. This is a disea…

This study tested a new drug called bimekizumab in 567 adults with moderate to severe plaque psoriasis. The goal was to see if it could clear skin better than a placebo or an existing treatment. Participants received injections and were monitored for improvement in skin redness, …

This study looked at how well risankizumab works compared to other biologic drugs for adults with moderate to severe plaque psoriasis. About 2,759 participants were followed to see how many achieved significant skin clearance and how long they stayed on their treatment. The goal …

This study looked at the long-term safety of bimekizumab, a drug for moderate to severe plaque psoriasis, in over 1,300 adults. Participants who had completed earlier studies received the drug for up to several years. The main goal was to track side effects and see how well the b…

This study tested a new drug called bimekizumab in 49 adults with moderate to severe plaque psoriasis. The goal was to see how well it clears skin, how long it stays in the body, and if it is safe. Participants received the drug and were followed for 28 weeks to track changes in …

This study tested a new drug called bimekizumab against an existing drug, secukinumab, in 743 adults with moderate to severe plaque psoriasis. The main goal was to see how many people achieved complete skin clearance after 16 weeks of treatment. Both drugs are biologics that help…

This study tested a drug called bimekizumab against a placebo in 435 adults with moderate to severe plaque psoriasis. The goal was to see if the drug could clear or nearly clear skin patches. Results showed significant improvement in skin symptoms for those taking bimekizumab.

This study tested a new drug called bimekizumab against an existing treatment (adalimumab) in 478 adults with moderate to severe plaque psoriasis. The main goal was to see how many people achieved at least 90% clearer skin after 16 weeks of treatment. The trial also looked at lon…